MICHAEL Y. CHO MD
Prescription History 1487970950
Internal Medicine - Hematology & Oncology in Los Angeles, CA

NPI Status: Active since April 08, 2010

Contact Information

6041 CADILLAC AVE
LOS ANGELES, CA
ZIP 90034
Phone: (301) 514-7397

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MICHAEL Y. CHO MD, an active Hematology & Oncology specialist practicing in Los Angeles, CA. Our medical registry currently tracks 50 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 2,494 documented patient claims. Among these therapy options, the most frequently utilized medication is Abiraterone Acetate, which accounts for 470 claims alone.


Abiraterone Acetate

Generic Formulation: Abiraterone AcetateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 470
30-Day Fills 473.0
Days Supply 14,190
CA State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills51.1
Peer Average Days Supply1,527
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 879.2% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $69,476.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$147.82

State Avg Cost Per Claim

$1,946.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Therapeutic Applications

This medication is used to treat prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children.

Acetaminophen-Codeine

Generic Formulation: Acetaminophen With CodeineSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 50
CA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.2
Peer Average Days Supply475
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $172.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.48

State Avg Cost Per Claim

$16.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

See also Warning section. This combination medication is used to help relieve mild to moderate pain. It contains an opioid pain reliever (codeine) and a non-opioid pain reliever (acetaminophen). Codeine works in the brain to change how your body feels and responds to pain. Acetaminophen can also reduce a fever.

Acyclovir

Generic Formulation: AcyclovirSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 64
30-Day Fills 128.4
Days Supply 3,828
CA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills38.5
Peer Average Days Supply971
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 166.7% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,870.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.22

State Avg Cost Per Claim

$26.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Alecensa

Generic Formulation: Alectinib HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 22.3
Days Supply 670
CA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills17.0
Peer Average Days Supply509
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $370,560.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$18,528.03

State Avg Cost Per Claim

$16,833.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Alectinib is used to treat a certain type of lung cancer. It works by slowing or stopping the growth of cancer cells. Alectinib belongs to a class of drugs known as tyrosine kinase inhibitors.

Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 29
30-Day Fills 80.3
Days Supply 2,407
CA State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills138.0
Peer Average Days Supply4,109
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $300.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.36

State Avg Cost Per Claim

$12.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Allopurinol

Generic Formulation: AllopurinolSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 23.0
Days Supply 597
CA State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills110.3
Peer Average Days Supply3,283
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.7% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $109.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.09

State Avg Cost Per Claim

$15.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.

Therapeutic Applications

Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 44
30-Day Fills 131.6
Days Supply 3,950
CA State Average Benchmarks
Peer Average Claims68.0
Peer Average 30-Day Fills165.7
Peer Average Days Supply4,950
Conservative Utilization

This provider writes prescriptions for this formulation 35.3% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,082.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.60

State Avg Cost Per Claim

$27.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Bicalutamide

Generic Formulation: BicalutamideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 26.3
Days Supply 754
CA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills56.8
Peer Average Days Supply1,657
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.3% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $370.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.73

State Avg Cost Per Claim

$38.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Bicalutamide is used to treat prostate cancer. This medication works by blocking the action of male hormones in the prostate, slowing the growth of cancer cells. This medication should not be used in women and children.

Brukinsa

Generic Formulation: ZanubrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 47
30-Day Fills 47.0
Days Supply 1,410
CA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.4
Peer Average Days Supply728
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 95.8% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $235,057.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,001.22

State Avg Cost Per Claim

$11,990.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia). Zanubrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Cabometyx

Generic Formulation: Cabozantinib S-MalateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 42
30-Day Fills 42.0
Days Supply 1,260
CA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.9
Peer Average Days Supply625
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 110.0% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $882,007.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$21,000.18

State Avg Cost Per Claim

$24,238.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat various types of cancer (including kidney, thyroid, liver cancer). Cabozantinib belongs to a class of drugs known as tyrosine kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Calquence

Generic Formulation: Acalabrutinib MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 600
CA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.6
Peer Average Days Supply495
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $217,190.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$10,859.52

State Avg Cost Per Claim

$14,069.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 85
30-Day Fills 92.0
Days Supply 1,407
CA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills36.0
Peer Average Days Supply559
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 165.6% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,639.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.29

State Avg Cost Per Claim

$19.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 47
30-Day Fills 114.2
Days Supply 3,428
CA State Average Benchmarks
Peer Average Claims68.0
Peer Average 30-Day Fills112.8
Peer Average Days Supply3,201
Conservative Utilization

This provider writes prescriptions for this formulation 30.9% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $60,306.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,283.12

State Avg Cost Per Claim

$848.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Entecavir

Generic Formulation: EntecavirSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 30.6
Days Supply 919
CA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills58.4
Peer Average Days Supply1,746
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.1% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $780.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$70.93

State Avg Cost Per Claim

$283.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

See also Warning section. Entecavir is used to treat long-term hepatitis B infection. Hepatitis B is an infection of the liver caused by the hepatitis B virus. Long-term infection can cause liver damage, rarely liver cancer, and liver failure. Entecavir helps to decrease the amount of hepatitis B virus in your body. It is unknown if this medication lowers your chance of getting liver cancer or liver damage. Entecavir is an antiviral that belongs to a class of drugs known as hepatitis B virus nucleoside reverse transcriptase inhibitors. Entecavir is not a cure for hepatitis B. It does not prevent the spread of the virus to others through sexual contact or blood/body fluid contamination (such as sharing used needles).

Erleada

Generic Formulation: ApalutamideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 510
CA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills27.2
Peer Average Days Supply812
Conservative Utilization

This provider writes prescriptions for this formulation 34.6% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $131,875.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$7,757.40

State Avg Cost Per Claim

$14,394.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apalutamide is used to treat men with prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Erlotinib Hcl

Generic Formulation: Erlotinib HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
CA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.6
Peer Average Days Supply519
Conservative Utilization

This provider writes prescriptions for this formulation 29.4% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $898.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$74.85

State Avg Cost Per Claim

$1,385.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER.

Therapeutic Applications

Erlotinib is used to treat lung and pancreatic cancer. It works by slowing or stopping the growth of cancer cells.

Everolimus

Generic Formulation: EverolimusSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 547
CA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills19.6
Peer Average Days Supply565
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $22,013.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,100.69

State Avg Cost Per Claim

$4,776.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT.

Therapeutic Applications

Everolimus is used to treat various types of cancer (such as kidney, breast, pancreas, lung, stomach/intestinal cancers). Everolimus is also used in people with a certain genetic disorder (tuberous sclerosis complex) to treat certain types of benign tumors in the brain or kidney. It works by slowing or stopping the growth of cancer or tumor cells.

Exemestane

Generic Formulation: ExemestaneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 87
30-Day Fills 238.4
Days Supply 7,152
CA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills59.9
Peer Average Days Supply1,785
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 222.2% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,821.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$89.90

State Avg Cost Per Claim

$259.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Furosemide

Generic Formulation: FurosemideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 24
30-Day Fills 33.2
Days Supply 734
CA State Average Benchmarks
Peer Average Claims65.0
Peer Average 30-Day Fills133.2
Peer Average Days Supply3,865
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.1% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $212.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.85

State Avg Cost Per Claim

$7.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.

Therapeutic Applications

Furosemide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This can lessen symptoms such as shortness of breath and swelling in your arms, legs, and abdomen. This drug is also used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Furosemide is a water pill (diuretic) that causes you to make more urine. This helps your body get rid of extra water and salt.

Gabapentin

Generic Formulation: GabapentinSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 45
30-Day Fills 53.5
Days Supply 1,578
CA State Average Benchmarks
Peer Average Claims81.0
Peer Average 30-Day Fills134.7
Peer Average Days Supply3,929
Conservative Utilization

This provider writes prescriptions for this formulation 44.4% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $853.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.96

State Avg Cost Per Claim

$21.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Hydrocodone-Acetaminophen

Generic Formulation: Hydrocodone/AcetaminophenSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 41
30-Day Fills 41.0
Days Supply 443
CA State Average Benchmarks
Peer Average Claims79.0
Peer Average 30-Day Fills79.9
Peer Average Days Supply1,693
Conservative Utilization

This provider writes prescriptions for this formulation 48.1% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $768.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.74

State Avg Cost Per Claim

$22.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to relieve moderate to severe pain. It contains an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen). Hydrocodone works in the brain to change how your body feels and responds to pain. Acetaminophen can also reduce a fever.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 75
30-Day Fills 228.0
Days Supply 6,817
CA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills69.5
Peer Average Days Supply2,062
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 127.3% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,132.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$41.77

State Avg Cost Per Claim

$42.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Ibrance

Generic Formulation: PalbociclibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 329
CA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills29.0
Peer Average Days Supply769
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.1% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $167,833.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,986.13

State Avg Cost Per Claim

$14,455.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Palbociclib is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells.

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 30
30-Day Fills 30.0
Days Supply 900
CA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills24.4
Peer Average Days Supply728
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 36.4% more claims than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,806.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$60.21

State Avg Cost Per Claim

$1,586.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Imbruvica

Generic Formulation: IbrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 28
30-Day Fills 28.0
Days Supply 826
CA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills29.0
Peer Average Days Supply826
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $274,873.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,816.91

State Avg Cost Per Claim

$15,007.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Inlyta

Generic Formulation: AxitinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
CA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.1
Peer Average Days Supply503
Conservative Utilization

This provider writes prescriptions for this formulation 35.3% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $236,009.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$21,455.41

State Avg Cost Per Claim

$16,949.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzamide and indazole derivative that acts as a TYROSINE KINASE inhibitor of the VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR. It is used in the treatment of advanced RENAL CELL CARCINOMA.

Therapeutic Applications

This medication is used to treat kidney cancer. Axitinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as tyrosine kinase inhibitors.

Kisqali

Generic Formulation: Ribociclib SuccinateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 627
CA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.6
Peer Average Days Supply457
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 56.3% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $239,003.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,560.12

State Avg Cost Per Claim

$14,551.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Ribociclib is used to treat breast cancer. It works by slowing or stopping the growth of cancer cells.

Lenalidomide

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 539
CA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.3
Peer Average Days Supply700
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $221,340.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$11,067.01

State Avg Cost Per Claim

$12,446.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Lenvima

Generic Formulation: Lenvatinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
CA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.5
Peer Average Days Supply550
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $363,543.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$20,196.86

State Avg Cost Per Claim

$21,869.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat cancer. Lenvatinib belongs to a class of drugs known as tyrosine kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 46
30-Day Fills 125.9
Days Supply 3,779
CA State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills111.8
Peer Average Days Supply3,337
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $800.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.40

State Avg Cost Per Claim

$32.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Levothyroxine Sodium

Generic Formulation: Levothyroxine SodiumSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 34.0
Days Supply 1,020
CA State Average Benchmarks
Peer Average Claims124.0
Peer Average 30-Day Fills305.1
Peer Average Days Supply9,029
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 85.5% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $272.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.17

State Avg Cost Per Claim

$19.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

Therapeutic Applications

Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally produced by the thyroid gland. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone is important for maintaining normal mental and physical activity. In children, having enough thyroid hormone is important for normal mental and physical development. This medication is also used to treat other types of thyroid disorders (such as thyroid cancer). This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.

Lonsurf

Generic Formulation: Trifluridine/Tipiracil HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 212
CA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.5
Peer Average Days Supply412
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $222,708.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,100.50

State Avg Cost Per Claim

$11,724.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as stomach, colon/rectum). It works by slowing or stopping the growth of cancer cells.

Lorazepam

Generic Formulation: LorazepamSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 176
CA State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills48.5
Peer Average Days Supply1,223
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.1% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $78.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.06

State Avg Cost Per Claim

$7.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.

Therapeutic Applications

This medication is used to treat serious seizures that do not stop (status epilepticus). It is also used before surgeries or procedures to cause drowsiness, decrease anxiety, and cause forgetfulness about the procedure or surgery. Lorazepam belongs to a class of medications called benzodiazepines, which produce a calming effect on the brain and nerves (central nervous system). It is thought to work by increasing the effect of a certain natural chemical (GABA) in the brain.

Lynparza

Generic Formulation: OlaparibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 55
30-Day Fills 55.0
Days Supply 1,529
CA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.5
Peer Average Days Supply553
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 205.6% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $652,778.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$11,868.70

State Avg Cost Per Claim

$13,776.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as breast, ovarian, fallopian tube, pancreatic, peritoneal cancer, prostate). Olaparib works by slowing or stopping the growth of cancer cells.

Methotrexate

Generic Formulation: Methotrexate SodiumSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 364
CA State Average Benchmarks
Peer Average Claims93.0
Peer Average 30-Day Fills185.8
Peer Average Days Supply5,474
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 86.0% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $141.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.85

State Avg Cost Per Claim

$40.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.

Therapeutic Applications

Methotrexate is used to treat certain types of cancer (such as acute lymphoblastic leukemia, non-Hodgkin's lymphoma) or to control severe psoriasis or rheumatoid arthritis that has not responded to other treatments. It may also be used to control juvenile rheumatoid arthritis. Methotrexate belongs to a class of drugs known as antimetabolites. It works by slowing or stopping the growth of cancer cells and suppressing the immune system. Early treatment of rheumatoid arthritis with more aggressive therapy such as methotrexate helps to reduce further joint damage and to preserve joint function.

Mirtazapine

Generic Formulation: MirtazapineSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 30
30-Day Fills 47.3
Days Supply 1,420
CA State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills64.1
Peer Average Days Supply1,845
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $292.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.74

State Avg Cost Per Claim

$22.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.

Therapeutic Applications

Mirtazapine is used to treat depression. It improves mood and feelings of well-being. Mirtazapine is an antidepressant that works by restoring the balance of natural chemicals (neurotransmitters) in the brain.

Nivestym

Generic Formulation: Filgrastim-AafiSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 81
30-Day Fills 81.0
Days Supply 432
CA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.4
Peer Average Days Supply186
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 268.2% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $63,400.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$782.73

State Avg Cost Per Claim

$823.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Filgrastim is a man-made version of a certain natural substance made by your body. It is used to help your body make more white blood cells. White blood cells are important to help you fight off infections. Filgrastim is given to people whose ability to make white blood cells is reduced (for instance, due to chemotherapy, chronic neutropenia, or exposure to large amounts of radiation). It is also used in certain treatment procedures (such as bone marrow/stem cell transplant). This monograph is about the following filgrastim products: filgrastim, tbo-filgrastim, filgrastim-sndz, filgrastim-aafi, and filgrastim-ayow.

Nubeqa

Generic Formulation: DarolutamideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 65
30-Day Fills 65.0
Days Supply 1,950
CA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.5
Peer Average Days Supply792
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 150.0% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $627,673.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,656.52

State Avg Cost Per Claim

$12,185.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Darolutamide is used to treat a certain type of prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 29
30-Day Fills 32.0
Days Supply 633
CA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.5
Peer Average Days Supply570
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $287.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.92

State Avg Cost Per Claim

$8.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Ondansetron Odt

Generic Formulation: OndansetronSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 47
30-Day Fills 47.0
Days Supply 464
CA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.3
Peer Average Days Supply245
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 113.6% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $545.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.61

State Avg Cost Per Claim

$21.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. Ondansetron works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Oxycodone-Acetaminophen

Generic Formulation: Oxycodone Hcl/AcetaminophenSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.0
Days Supply 208
CA State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills48.7
Peer Average Days Supply1,076
Conservative Utilization

This provider writes prescriptions for this formulation 43.8% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $471.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.45

State Avg Cost Per Claim

$31.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to help relieve moderate to severe pain. It contains an opioid pain reliever (oxycodone) and a non-opioid pain reliever (acetaminophen). Oxycodone works in the brain to change how your body feels and responds to pain. Acetaminophen can also reduce a fever.

Potassium Chloride

Generic Formulation: Potassium ChlorideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 65
30-Day Fills 90.1
Days Supply 2,167
CA State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills98.7
Peer Average Days Supply2,867
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 35.4% more claims than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,502.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$38.50

State Avg Cost Per Claim

$34.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.

Therapeutic Applications

This medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood. A normal level of potassium in the blood is important. Potassium helps your cells, kidneys, heart, muscles, and nerves work properly. Most people get enough potassium by eating a well-balanced diet. Some conditions that can lower your body's potassium level include severe prolonged diarrhea and vomiting, hormone problems such as hyperaldosteronism, or treatment with water pills/diuretics.

Pradaxa

Generic Formulation: Dabigatran Etexilate MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 40
30-Day Fills 81.7
Days Supply 2,450
CA State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills130.8
Peer Average Days Supply3,890
Conservative Utilization

This provider writes prescriptions for this formulation 25.9% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,493.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$212.34

State Avg Cost Per Claim

$487.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.

Therapeutic Applications

Dabigatran is used to prevent stroke and harmful blood clots (such as in your legs or lungs) if you have a certain type of irregular heartbeat (atrial fibrillation). Dabigatran is also used to treat blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) and to reduce the risk of them occurring again. This medication may also be used to prevent these blood clots from forming after hip replacement surgery. Dabigatran is an anticoagulant that works by blocking a certain substance (a clotting protein called thrombin) in your blood. This helps to keep blood flowing smoothly in your body. Dabigatran should not be used to prevent blood clots from forming after artificial heart valve replacement. If you have had heart valve surgery, talk to your doctor about the best medication for you. Do not stop taking any medication, including dabigatran, without talking to your doctor first.

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 320
30-Day Fills 657.5
Days Supply 19,626
CA State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills52.2
Peer Average Days Supply1,075
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 700.0% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,798.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.74

State Avg Cost Per Claim

$8.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 36
30-Day Fills 36.0
Days Supply 312
CA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.9
Peer Average Days Supply353
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 28.6% more claims than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $529.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.70

State Avg Cost Per Claim

$18.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 41.3
Days Supply 1,239
CA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills27.8
Peer Average Days Supply371
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $153.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.10

State Avg Cost Per Claim

$5.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Tagrisso

Generic Formulation: Osimertinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 780
CA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills32.4
Peer Average Days Supply969
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $428,630.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,485.80

State Avg Cost Per Claim

$16,956.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat lung cancer. Osimertinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 68
30-Day Fills 215.9
Days Supply 6,453
CA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills83.0
Peer Average Days Supply2,479
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 100.0% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,366.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.80

State Avg Cost Per Claim

$36.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 30
30-Day Fills 79.0
Days Supply 2,370
CA State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills79.1
Peer Average Days Supply2,270
Conservative Utilization

This provider writes prescriptions for this formulation 31.8% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $34,648.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,154.93

State Avg Cost Per Claim

$907.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Xtandi

Generic Formulation: EnzalutamideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 67
30-Day Fills 67.0
Days Supply 2,008
CA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.9
Peer Average Days Supply925
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 123.3% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $644,992.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,626.76

State Avg Cost Per Claim

$12,773.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enzalutamide is used to treat prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MICHAEL Y. CHO MD provides transparency into local medical care patterns within Los Angeles, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.